Angiogenesis plays an important role in tumor growth, invasion, and eventually metastasis. Antiangiogenic strategies have been proven to be a promising approach for clinical therapy for a variety of tumors. As a potent inhibitor of tumor angiogenesis, pigment epithelium-derived factor (PEDF) has recently been studied and used as an anticancer agent in several tumor models.
10 September 2021 in Pathology and Oncology Research
Introduction: Gastric cancer is one of the most common cancers. Although some progress has been made in the treatment of gastric cancer with the improvement of surgical methods and the application of immunotherapy, the prognosis of gastric cancer patients is still unsatisfactory. In recent years, there has been increasing evidence that tumor mutational load (TMB) is strongly associated with survival outcomes and response to immunotherapy. Given the variable response of patients to immunotherapy, it is important to investigate clinical significance of TMB and explore appropriate biomarkers of prognosis in patients with gastric cancer (GC).Material and Methods: All data of patients with gastric cancer were obtained from the database of The Cancer Genome Atlas (TCGA). Samples were divided into two groups based on median TMB. Differently expressed genes (DEGs) between the high- and low-TMB groups were identified and further analyzed. We identified TMB-related genes using Lasso, univariate and multivariate Cox regression analysis and validated the survival result of 11 hub genes using Kaplan-Meier Plotter. In addition, “CIBERSORT” package was utilized to estimate the immune infiltration.Results: Single nucleotide polymorphism (SNP), C > T transition were the most common variant type and single nucleotide variant (SNV), respectively. Patients in the high-TMB group had better survival outcomes than those in the low-TMB group. Besides, eleven TMB-related DEGs were utilized to construct a prognostic model that could be an independent risk factor to predict the prognosis of patients with GC. What’s more, the infiltration levels of CD4+ memory-activated T cells, M0 and M1 macrophages were significantly increased in the high-TMB group compared with the low-TMB group.Conclusions: Herein, we found that patients with high TMB had better survival outcomes in GC. In addition, higher TMB might promote immune infiltration, which could provide new ideas for immunotherapy.
Background: Sarcomatoid urothelial carcinoma (SUC) is a rare, highly aggressive subtype of urothelial carcinoma (UC) accounting for fewer than 1%–2% of all urothelial malignancies. It is characterized by biphasic histology, a dismal prognosis, resistance to conventional chemotherapy, and a propensity for distant metastasis. Clinically confirmed cardiac metastasis from UC is exceedingly rare, with only sporadic cases documented worldwide. Case summary: We report a 55-year-old woman who presented with right-sided flank pain and gross hematuria. Percutaneous renal biopsy confirmed right renal pelvis SUC with approximately 85% sarcomatoid component. The patient underwent palliative robot-assisted laparoscopic nephroureterectomy; final pathological staging was pT3N1M1 (Stage IV). Approximately two months postoperatively, imaging confirmed multifocal metastases involving the lungs, pleura, liver, and lymph nodes, and first-line chemo-immunotherapy was initiated with gemcitabine plus carboplatin plus nivolumab. Carboplatin was substituted for cisplatin because the patient was deemed cisplatin-ineligible owing to renal insufficiency, following a modified CheckMate 901 framework. After one cycle, grade IV myelosuppression (platelet nadir 28 × 10 9 /L) necessitated permanent discontinuation of cytotoxic agents. During myelosuppression recovery, the patient developed palpitations; echocardiography revealed a large, broad-based right ventricular (RV) mass (50 × 41 mm). Treatment was revised to tislelizumab monotherapy (200 mg, every three weeks [q3w]). Serial echocardiographic follow-up documented progressive RV mass regression from 50 × 41 mm to 22 × 32 mm and ultimately to 11 × 14 mm, with stable systemic disease throughout. Conclusion: To our knowledge, this is the first documented case of isolated RV metastasis from right renal pelvis SUC achieving an objective response to anti-PD-1 immunotherapy. The sustained imaging regression under tislelizumab monotherapy strongly suggests—but does not definitively confirm—a metastatic etiology. For patients with high PD-L1–expressing SUC and cardiac metastasis who are intolerant of combined chemo-immunotherapy regimens, immune checkpoint inhibitor monotherapy may represent a feasible and well-tolerated treatment strategy.